Being able to remotely monitor patients’ mobility in their natural environment is a major advantage, both in lockdown and in general. To meet the societal need for better mobility assessment, Mobilise-D will follow up the ongoing technical validation study with a large-scale clinical study that will include 2400 patients from four different cohorts across different sites in Europe.

Mobility is often said to be a sixth vital sign, just as important as other vital signs such as blood pressure and heart rate, and the key to independence in our daily life. But what does mobility actually mean for people? And what happens when they experience mobility loss?

We asked several people what the importance of mobility is for them, and what the impact was when they experienced mobility loss. Here are some of their answers.

Prof. Lynn Rochester and Dr. Ronenn Roubenoff explain how mobility is a vital sign and the benefits of being able to measure people’s mobility in a reliable way. To achieve a robust digital mobility outcome, Mobilise-D will first have to overcome a few challenges. More about this in the video.

Mobilise-D technology for remote monitoring of patients’ daily-life mobility! Interview with Lynn Rochester, Professor of Human Movement Science, Institute of neuroscience, Newcastle University, the Academic Lead of Mobilise-D and Ronenn Roubenoff, Global Head, Translational Medicine Discovery & Profiling, Novartis Institutes for Biomedical Research, the EFPIA Co-lead of Mobilise-D.

D7.3 Guidelines for open access and data sharing

This deliverable provides the general framework regarding the sharing of data outside of the consortium, together with D1.3 Mobilise-D Data Management Plan and the Consortium Agreement.

D7.2 Report on publications, presentations, and event organisation

This deliverable reports on the publications, presentations, and events organised from M1 to M12 by the Mobilise-D consortium.

D4.1 Updated systematic review on primary and secondary clinical endpoints

This deliverable reports on the objectives, research questions, protocol, current status, project plan and, where available, preliminary results of reviews undertaken by Mobilise-D.

D3.1 Detailed system requirements specification, including definition of data acquisition, transmission, integration, processing, analytics and governance requirements

This deliverable describes the requirements for data capture, ingestion, and integration in the Technical Validation Study and Clinical Validation Study in Mobilise-D.

D2.3 First study subject approvals package

This deliverable details the protocol for the technical validation study within Mobilise-D, where specifically the design, recruitment, and data collection are described.

D2.2 Gold standard solutions for technical validation

This deliverable details the development of the gold standard solutions for the technical validation study within Mobilise-D.

D2.1 Digital mobility database of existing real-world and laboratory data and algorithms

This deliverable reports on the work done to enable the first step of the validation process.

D7.1 Communication and Dissemination Strategy, including project identity

This deliverable describes the communication and dissemination strategy, defines the dissemination channels and specific messages for the relevant stakeholders, the tools to monitor and evaluate communication and dissemination, and gives an overview of the dissemination materials that will be developed and used during the project.

D1.3 Data Management Plan V1

This deliverable provides the first version of the Mobilise-D Data Management Plan (DMP).

D1.2 Risk assessment process and management procedure

This deliverable details the procedure within Mobilise-D by which the project risks are identified, categorised and monitored.

D1.1 Project Handbook

This deliverable acts as a reference source for all Consortium members and standardises various elements of the project.